HT
NKTR icon

Headlands Technologies’s Nektar Therapeutics NKTR Stock Holding History

Headlands Technologies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.03M Sell
28,244
-12,957
-31% -$738K 0.23% 86
2025
Q4 		$1.74M Buy
41,201
+11,371
+38% +$636K 0.15% 164
2025
Q3 		$1.7M Buy
29,830
+27,308
+1,083% +$904K 0.14% 167
2025
Q2 		$65.2K Buy
+2,522
New +$28.3K 0.01% 721

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Headlands Technologies's NKTR Position: Q1 2026 in Review

Headlands Technologies reduced its Nektar Therapeutics (NKTR) stake by 31% in Q1 2026, selling an estimated $738K and leaving 28,244 shares worth $2.03M. The position accounts for 0.23% of the portfolio, ranked #86.

Headlands Technologies first reported a position in NKTR in Q2 2025 and has held it in 4 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Headlands Technologies held 28,244 shares of Nektar Therapeutics worth $2.03M as of Q1 2026.
  • Headlands Technologies sold 12,957 Nektar Therapeutics shares in Q1 2026, an estimated $738K.
  • Nektar Therapeutics made up 0.23% of Headlands Technologies's portfolio in Q1 2026, its #86 holding.
  • Headlands Technologies first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.